Cargando…
Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome
Wnt signaling activates the canonical pathway and induces the accumulation of non-phosphorylated beta-catenin (NPBC) in the nucleus. Although this pathway plays an important role in the maintenance of haematopoietic stem cells as well as in oncogenesis, the significance of nuclear NPBC remains uncle...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Blackwell Publishing Ltd
2008
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2253692/ https://www.ncbi.nlm.nih.gov/pubmed/18217891 http://dx.doi.org/10.1111/j.1365-2141.2007.06914.x |
_version_ | 1782151128382701568 |
---|---|
author | Xu, Jinglan Suzuki, Momoko Niwa, Yousuke Hiraga, Junji Nagasaka, Tetsuro Ito, Masafumi Nakamura, Shigeo Tomita, Akihiro Abe, Akihiro Kiyoi, Hitoshi Kinoshita, Tomohiro Naoe, Tomoki |
author_facet | Xu, Jinglan Suzuki, Momoko Niwa, Yousuke Hiraga, Junji Nagasaka, Tetsuro Ito, Masafumi Nakamura, Shigeo Tomita, Akihiro Abe, Akihiro Kiyoi, Hitoshi Kinoshita, Tomohiro Naoe, Tomoki |
author_sort | Xu, Jinglan |
collection | PubMed |
description | Wnt signaling activates the canonical pathway and induces the accumulation of non-phosphorylated beta-catenin (NPBC) in the nucleus. Although this pathway plays an important role in the maintenance of haematopoietic stem cells as well as in oncogenesis, the significance of nuclear NPBC remains unclear in malignant haematopoiesis. This study examined the expression of nuclear NPBC in bone marrow specimens from 54 and 44 patients with de novo acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), respectively. On immunohistochemistry with an anti-NPBC antibody, the nuclei were positively stained in 22 and 18 of AML and MDS specimens, respectively. Staining of nuclear NPBC was associated with AML subtypes (M6 and M7), low complete remission (CR) rate, and poor prognosis. Nuclear NPBC was also associated with a high score when using the International Prognostic Scoring System (IPSS) for MDS and with −7/−7q and complex karyotypes. These findings suggest that in situ detection of nuclear NPBC by immunohistochemistry could provide new insights into the pathogenesis and prognosis of AML and MDS. |
format | Text |
id | pubmed-2253692 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2008 |
publisher | Blackwell Publishing Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-22536922008-03-10 Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome Xu, Jinglan Suzuki, Momoko Niwa, Yousuke Hiraga, Junji Nagasaka, Tetsuro Ito, Masafumi Nakamura, Shigeo Tomita, Akihiro Abe, Akihiro Kiyoi, Hitoshi Kinoshita, Tomohiro Naoe, Tomoki Br J Haematol Haematological Malignancy Wnt signaling activates the canonical pathway and induces the accumulation of non-phosphorylated beta-catenin (NPBC) in the nucleus. Although this pathway plays an important role in the maintenance of haematopoietic stem cells as well as in oncogenesis, the significance of nuclear NPBC remains unclear in malignant haematopoiesis. This study examined the expression of nuclear NPBC in bone marrow specimens from 54 and 44 patients with de novo acute myeloid leukaemia (AML) and myelodysplastic syndrome (MDS), respectively. On immunohistochemistry with an anti-NPBC antibody, the nuclei were positively stained in 22 and 18 of AML and MDS specimens, respectively. Staining of nuclear NPBC was associated with AML subtypes (M6 and M7), low complete remission (CR) rate, and poor prognosis. Nuclear NPBC was also associated with a high score when using the International Prognostic Scoring System (IPSS) for MDS and with −7/−7q and complex karyotypes. These findings suggest that in situ detection of nuclear NPBC by immunohistochemistry could provide new insights into the pathogenesis and prognosis of AML and MDS. Blackwell Publishing Ltd 2008-02 /pmc/articles/PMC2253692/ /pubmed/18217891 http://dx.doi.org/10.1111/j.1365-2141.2007.06914.x Text en © 2008 The Authors Journal Compilation © 2008 Blackwell Publishing Ltd https://creativecommons.org/licenses/by/2.5/ Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation. |
spellingShingle | Haematological Malignancy Xu, Jinglan Suzuki, Momoko Niwa, Yousuke Hiraga, Junji Nagasaka, Tetsuro Ito, Masafumi Nakamura, Shigeo Tomita, Akihiro Abe, Akihiro Kiyoi, Hitoshi Kinoshita, Tomohiro Naoe, Tomoki Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome |
title | Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome |
title_full | Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome |
title_fullStr | Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome |
title_full_unstemmed | Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome |
title_short | Clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome |
title_sort | clinical significance of nuclear non-phosphorylated beta-catenin in acute myeloid leukaemia and myelodysplastic syndrome |
topic | Haematological Malignancy |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2253692/ https://www.ncbi.nlm.nih.gov/pubmed/18217891 http://dx.doi.org/10.1111/j.1365-2141.2007.06914.x |
work_keys_str_mv | AT xujinglan clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT suzukimomoko clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT niwayousuke clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT hiragajunji clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT nagasakatetsuro clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT itomasafumi clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT nakamurashigeo clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT tomitaakihiro clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT abeakihiro clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT kiyoihitoshi clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT kinoshitatomohiro clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome AT naoetomoki clinicalsignificanceofnuclearnonphosphorylatedbetacatenininacutemyeloidleukaemiaandmyelodysplasticsyndrome |